失代偿期肝硬化慢性病管理干预的多中心随机试验:澳大利亚肝衰竭(ALFIE)试验
该为期2年的多中心随机对照试验将147例失代偿期肝硬化出院患者按1:1分配至由肝病护士协调的多方面慢性病管理(CDM)模型组或常规照护组。结果显示干预未减少肝脏相关急诊入院总发生率(发生率比0.89,95%CI 0.53-1.50,P=0.666),也未改善生存,但肝性脑病相关急诊入院风险降低,骨密度、维生素D检测及肝癌监测依从性等照护质量指标改善。
要点
- CDM干预未降低失代偿期肝硬化患者肝脏相关急诊入院总发生率及死亡率。
- 干预组肝性脑病相关急诊入院风险较对照组降低(HR=1.87,95%CI 1.18-2.96,P=0.007)。
- 骨密度、维生素D检测及肝癌监测依从性等照护质量指标显著改善。
核心结论
- 该CDM干预未减少肝脏相关急诊入院总事件,对于该终点在失代偿期肝硬化中可能无效。
研究设计与样本
- 为期2年的多中心随机对照研究,按1:1分配至CDM模型组或常规照护组,设置包括三级和社区照护。
- 共纳入147例失代偿期肝硬化出院后患者(干预组75例,对照组71例),中位MELD评分为19。
- 干预为由肝病护士协调的多方面CDM模型。
主要发现
- 干预组与对照组肝脏相关急诊入院总发生率无差异(发生率比0.89;95%CI 0.53-1.50,P=0.666)。
- 两组生存无差异(HR=1.14;95%CI 0.66-1.96,P=0.646)。
- 干预组较对照组肝性脑病相关肝脏相关急诊入院风险降低(HR=1.87;95%CI 1.18-2.96,P=0.007)。
- 骨密度执行(P<0.001)、维生素D检测(P<0.001)及肝癌监测依从性(P=0.050)等照护质量指标显著改善。
- 可评估参与者(干预组44/74,对照组32/71)在3个月时自我管理能力和视觉模拟量表评估的生活质量等患者报告结局显著改善(P=0.044)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Improving the care of decompensated cirrhosis is a significant clinical challenge. The primary aim of this trial was to assess the efficacy of a chronic disease management (CDM) model to reduce liver-related emergency admissions (LREA). The secondary aims were to assess model effects on quality-of-care and patient-reported outcomes. APPROACH AND RESULTS: The study design was a 2-year, multicenter, randomized controlled study with 1:1 allocation of a CDM model versus usual care. The study setting involved both tertiary and community care. Participants were randomly allocated following a decompensated cirrhosis admission. The intervention was a multifaceted CDM model coordinated by a liver nurse. A total of 147 participants (intervention=75, control=71) were recruited with a median Model for End-Stage Liver Disease score of 19. For the primary outcome, there was no difference in the overall LREA rate for the intervention group versus the control group (incident rate ratio 0.89; 95% CI: 0.53-1.50, p =0.666) or in actuarial survival (HR=1.14; 95% CI: 0.66-1.96, p =0.646). However, there was a reduced risk of LREA due to encephalopathy in the intervention versus control group (HR=1.87; 95% CI: 1.18-2.96, p =0.007). Significant improvement in quality-of-care measures was seen for the performance of bone density ( p <0.001), vitamin D testing ( p <0.001), and HCC surveillance adherence ( p =0.050). For assessable participants (44/74 intervention, 32/71 controls) significant improvements in patient-reported outcomes at 3 months were seen in self-management ability and quality of life as assessed by visual analog scale ( p =0.044). CONCLUSIONS: This CDM intervention did not reduce overall LREA events and may not be effective in decompensated cirrhosis for this end point.
引用
- Wigg AJ, Narayana S, Woodman RJ, et al. A randomized multicenter trial of a chronic disease management intervention for decompensated cirrhosis. The A ustra l ian L iver F a i lur e (ALFIE) trial. Hepatology. 2024. PMID: 38825975. doi:10.1097/HEP.0000000000000862
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。